Haleon (HLN) Debt Ratio (2021 - 2026)

Haleon's (HLN) quarterly Debt Ratio came in at 0.19 in Q2 2026, up 9.19% on a QoQ basis from 0.21 in Q4 2025.

Haleon (HLN) Debt Ratio (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Debt Ratio data on file, last reported at 0.19 in Q2 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.19 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.19 (changed N/A YoY) and the FY2025 annual result came in at 0.21, down 172.04% from the prior year.
Debt Ratio grew to 0.19 in Q2 2026, from 0.21 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.3 in Q4 2022 to a low of 0.22 in Q2 2023.
A 5-year average of 0.02 and a median of 0.19 in 2024 frame the typical range for Debt Ratio.
Annual changes were most pronounced in 2022 — Debt Ratio surged 6123.4% — and 2025, when it sank 172.04%.
Tracing HLN's Debt Ratio over 5 years: stood at 0.3 in 2022, then dropped by 7.4% to 0.28 in 2023, then climbed by 6.28% to 0.3 in 2024, then slumped by 172.04% to 0.21 in 2025, then increased by 9.19% to 0.19 in 2026.
The last three Debt Ratio figures came in at 0.19 (Q2 2026), 0.21 (Q4 2025), and 0.3 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn	0.42
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn	0.32
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn	-
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn	-
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	0.12
10	Alkermes	8.15 Bn	7.49 Bn	397.90 Mn	0.34

Download Data